BACKGROUND: Enterococci are an important cause of central venous catheter (CVC)-associated bloodstream infections (CA-BSI). It is unclear whether CVC removal is necessary to successfully manage enterococcal CA-BSI. METHODS: A 12-month retrospective cohort study of adults with enterococcal CA-BSI was conducted at a tertiary care hospital; clinical, microbiological and outcome data were collected. RESULTS: A total of 111 patients had an enterococcal CA-BSI. The median age was 58.2 years (range 21 to 94 years). There were 45 (40.5%) infections caused by Entercoccus faecalis (among which 10 [22%] were vancomycin resistant), 61 (55%) by Enterococcus faecium (57 [93%] vancomycin resistant) and five (4.5%) by other Enterococcus species. Patients were treated with linezolid (n=51 [46%]), vancomycin (n=37 [33%]), daptomycin (n=11 [10%]), ampicillin (n=2 [2%]) or quinupristin/dalfopristin (n=2 [2%]); seven (n=6%) patients did not receive adequate enterococcal treatment. Additionally, 24 (22%) patients received adjunctive gentamicin treatment. The CVC was retained in 29 (26.1%) patients. Patients with removed CVCs showed lower rates of in-hospital mortality (15 [18.3%] versus 11 [37.9]; P=0.03), but similar rates of recurrent bacteremia (nine [11.0%] versus two (7.0%); P=0.7) and a similar post-BSI length of hospital stay (median days [range]) (11.1 [1.7 to 63.1 days] versus 9.3 [1.9 to 31.8 days]; P=0.3). Catheter retention was an independent predictor of mortality (OR 3.34 [95% CI 1.21 to 9.26]). CONCLUSIONS: To the authors' knowledge, the present article describes the largest enterococcal CA-BSI series to date. Mortality was increased among patients who had their catheter retained. Additional prospective studies are necessary to determine the optimal management of enterococcal CA-BSI.
BACKGROUND: Enterococci are an important cause of central venous catheter (CVC)-associated bloodstream infections (CA-BSI). It is unclear whether CVC removal is necessary to successfully manage enterococcal CA-BSI. METHODS: A 12-month retrospective cohort study of adults with enterococcal CA-BSI was conducted at a tertiary care hospital; clinical, microbiological and outcome data were collected. RESULTS: A total of 111 patients had an enterococcal CA-BSI. The median age was 58.2 years (range 21 to 94 years). There were 45 (40.5%) infections caused by Entercoccus faecalis (among which 10 [22%] were vancomycin resistant), 61 (55%) by Enterococcus faecium (57 [93%] vancomycin resistant) and five (4.5%) by other Enterococcus species. Patients were treated with linezolid (n=51 [46%]), vancomycin (n=37 [33%]), daptomycin (n=11 [10%]), ampicillin (n=2 [2%]) or quinupristin/dalfopristin (n=2 [2%]); seven (n=6%) patients did not receive adequate enterococcal treatment. Additionally, 24 (22%) patients received adjunctive gentamicin treatment. The CVC was retained in 29 (26.1%) patients. Patients with removed CVCs showed lower rates of in-hospital mortality (15 [18.3%] versus 11 [37.9]; P=0.03), but similar rates of recurrent bacteremia (nine [11.0%] versus two (7.0%); P=0.7) and a similar post-BSI length of hospital stay (median days [range]) (11.1 [1.7 to 63.1 days] versus 9.3 [1.9 to 31.8 days]; P=0.3). Catheter retention was an independent predictor of mortality (OR 3.34 [95% CI 1.21 to 9.26]). CONCLUSIONS: To the authors' knowledge, the present article describes the largest enterococcal CA-BSI series to date. Mortality was increased among patients who had their catheter retained. Additional prospective studies are necessary to determine the optimal management of enterococcal CA-BSI.
Entities:
Keywords:
Bacteremia; Central venous catheter; Enterococcus; Management
Authors: Jonathan A T Sandoe; Ian R Witherden; Ho-Kong C Au-Yeung; Peter Kite; Kevin G Kerr; Mark H Wilcox Journal: J Antimicrob Chemother Date: 2002-10 Impact factor: 5.790
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: E Reigadas; M Rodríguez-Créixems; M Guembe; C Sánchez-Carrillo; P Martín-Rabadán; E Bouza Journal: Clin Microbiol Infect Date: 2012-05-22 Impact factor: 8.067
Authors: Nathan P Wiederhold; Elizabeth A Coyle; Issam I Raad; Randall A Prince; Russell E Lewis Journal: J Antimicrob Chemother Date: 2005-04-06 Impact factor: 5.790
Authors: Issam I Raad; Hend A Hanna; Maha Boktour; Gassan Chaiban; Ray Y Hachem; Tanya Dvorak; Russell Lewis; Barbara E Murray Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: A Zirakzadeh; D A Gastineau; J N Mandrekar; J P Burke; P B Johnston; R Patel Journal: Bone Marrow Transplant Date: 2007-12-17 Impact factor: 5.483
Authors: Jonathan A T Sandoe; Ian R Witherden; Jonathan H Cove; John Heritage; Mark H Wilcox Journal: J Med Microbiol Date: 2003-07 Impact factor: 2.472
Authors: Julia A Messina; Rohita Sinha; Kimberly Starr; Mehreen Arshad; Barbara D Alexander; Nelson J Chao; Anthony D Sung Journal: Open Forum Infect Dis Date: 2018-05-05 Impact factor: 3.835
Authors: S Dubler; M Lenz; S Zimmermann; D C Richter; K H Weiss; A Mehrabi; M Mieth; T Bruckner; M A Weigand; T Brenner; A Heininger Journal: Antimicrob Resist Infect Control Date: 2020-01-31 Impact factor: 4.887